Advertisement

Patient-Reported Outcomes in Oncology, Beyond Randomized Controlled Trials

  • Mondher Toumi
  • Szymon Jarosławski
  • Christos Chouhaid
  • Bruno Fallissard
  • P. Auquier
Chapter
Part of the Recent Results in Cancer Research book series (RECENTCANCER, volume 213)

Abstract

The goal of the treatment of a disease has moved from treating organs and diseases through symptoms, biological parameters and imaging towards treating a human being as a whole. The treatments should deliver benefits that patients can personally perceive. However, the patient’s perspective does not always match the one of those surrounding them. Illustratively, patients’ symptom assessments are more predictable for daily health status, whereas clinicians’ symptom measurements are more related to clinical outcomes. The term, patient-reported outcomes (PROs), includes any data that are reported directly by the patient without an intermediary, such as a family member or a healthcare professional. The use of PROs in oncology trials is increasing and the U.S. Food and Drug Administration has published guidelines on the review and evaluation of PROs. However, while PROs are increasingly used in clinical trials, they are rarely used in daily clinical practice. Further, healthcare payers are concerned with issues related to relevance, quality, and interpretability of these outcomes.

Keywords

Patient-reported outcomes (PROs) Health-related quality of life (HRQoL) Symptom assessment Oncology Payers Patient preference Clinical trials 

References

  1. Atkinson TM, Li Y, Coffey CW, Sit L, Shaw M, Lavene D, Bennett AV, Fruscione M, Rogak L, Hay J, Gonen M, Schrag D, Basch E (2012) Reliability of adverse symptom event reporting by clinicians. Qual Life Res 21(7):1159–1164.  https://doi.org/10.1007/s11136-011-0031-4CrossRefGoogle Scholar
  2. Au HJ, Ringash J, Brundage M, Palmer M, Richardson H, Meyer RM (2010) Added value of health-related quality of life measurement in cancer clinical trials: the experience of the NCIC CTG. Expert Rev Pharmacoecon Outcomes Res 10(2):119–128.  https://doi.org/10.1586/erp.10.15CrossRefPubMedGoogle Scholar
  3. Basch E (2015) Patient-centered endpoints in oncology sixth annual PRO consortium workshop. Critical Path Institute, PRO ConsortiumGoogle Scholar
  4. Basch E, Geoghegan C, Coons S et al (2015) Patient-reported outcomes in cancer drug development and us regulatory review: perspectives from industry, the food and drug administration, and the patient. JAMA Oncol 1(3):375–379.  https://doi.org/10.1001/jamaoncol.2015.0530CrossRefPubMedGoogle Scholar
  5. Blackhall F, Kim DW, Besse B, Nokihara H, Han JY, Wilner KD, Reisman A, Iyer S, Hirsh V, Shaw AT (2014) Patient-reported outcomes and quality of life in PROFILE 1007: a randomized trial of crizotinib compared with chemotherapy in previously treated patients with ALK-positive advanced non-small-cell lung cancer. J Thorac Oncol 9(11):1625–1633.  https://doi.org/10.1097/JTO.0000000000000318CrossRefPubMedGoogle Scholar
  6. Bridges JF, Onukwugha E, Johnson FR, Hauber AB (2007) Patient preference methods—a patient centered evaluation paradigm. ISPOR Connections DecemberGoogle Scholar
  7. Brundage M, Blazeby J, Revicki D, Bass B, de Vet H, Duffy H, Efficace F, King M, Lam CLK, Moher D, Scott J, Sloan J, Snyder C, Yount S, Calvert M (2013) Patient-reported outcomes in randomized clinical trials: development of ISOQOL reporting standards. Qual Life Res 22(6):1161–1175.  https://doi.org/10.1007/s11136-012-0252-1CrossRefPubMedGoogle Scholar
  8. Buyse M, Sargent DJ, Grothey A, Matheson A, de Gramont A (2010) Biomarkers and surrogate end points—the challenge of statistical validation. Nat Rev Clin Oncol 7(6):309–317. nrclinonc.2010.43 [pii]CrossRefGoogle Scholar
  9. Cella D, Grunwald V, Nathan P, Doan J, Dastani H, Taylor F, Bennett B, DeRosa M, Berry S, Broglio K, Berghorn E, Motzer RJ (2016) Quality of life in patients with advanced renal cell carcinoma given nivolumab versus everolimus in CheckMate 025: a randomised, open-label, phase 3 trial. Lancet Oncol 17(7):994–1003.  https://doi.org/10.1016/S1470-2045(16)30125-5CrossRefPubMedPubMedCentralGoogle Scholar
  10. Dawber R, Armour K, Ferry P, Mukherjee B, Carter C, Meystre C (2016) Comparison of informal caregiver and named nurse assessment of symptoms in elderly patients dying in hospital using the palliative outcome scale. BMJ Support Palliat Care.  https://doi.org/10.1136/bmjspcare-2015-000850CrossRefPubMedGoogle Scholar
  11. Ediebah DE, Coens C, Zikos E, Quinten C, Ringash J, King MT, Schmucker von Koch J, Gotay C, Greimel E, Flechtner H, Weis J, Reeve BB, Smit EF, Taphoorn MJ, Bottomley A (2014) Does change in health-related quality of life score predict survival? Analysis of EORTC 08975 lung cancer trial. Br J Cancer 110(10):2427–2433.  https://doi.org/10.1038/bjc.2014.208CrossRefPubMedPubMedCentralGoogle Scholar
  12. EHA (2011) Guidelines patient-reported outcomes in hematology scientific working group quality of life and symptoms. European Hematology AssociationGoogle Scholar
  13. EMA (2005) European Medicines Agency. Reflection paper on the regulatory guidance for the use of health related quality of life (HRQL) measures in the evaluation of medicinal products. European Medicines Agency, LondonGoogle Scholar
  14. Falchook AD, Green R, Knowles ME, Amdur RJ, Mendenhall W, Hayes DN, Grilley-Olson JE, Weiss J, Reeve BB, Mitchell SA, Basch EM, Chera BS (2016) Comparison of patient- and practitioner-reported toxic effects associated with chemoradiotherapy for head and neck Cancer. JAMA Otolaryngol Head Neck Surg 142(6):517–523.  https://doi.org/10.1001/jamaoto.2016.0656CrossRefPubMedPubMedCentralGoogle Scholar
  15. Friedlander M, Mercieca-Bebber RL, King MT (2016) Patient-reported outcomes (PRO) in ovarian cancer clinical trials-lost opportunities and lessons learned. Ann Oncol 27(Suppl 1):i66–i71.  https://doi.org/10.1093/annonc/mdw080CrossRefPubMedGoogle Scholar
  16. Gnanasakthy A, Mordin M, Clark M, DeMuro C, Fehnel S, Copley-Merriman C (2012) A review of patient-reported outcome labels in the United States: 2006 to 2010. Value Health 15(3):437–442.  https://doi.org/10.1016/j.jval.2011.11.032CrossRefPubMedGoogle Scholar
  17. Gotay CC, Kawamoto CT, Bottomley A, Efficace F (2008) The prognostic significance of patient-reported outcomes in cancer clinical trials. J Clin Oncol 26(8):1355–1363.  https://doi.org/10.1200/JCO.2007.13.3439CrossRefPubMedGoogle Scholar
  18. ISPOR (2001) The measurement of quality of life in clinical trials: considerations of good research practice. A Report of the ISPOR Health Science Committee—Task Force on Good Research Practices—Quality of Life Studies. ISPORGoogle Scholar
  19. Kim C, Prasad V (2015) Cancer drugs approved on the basis of a surrogate end point and subsequent overall survival: an analysis of 5 years of us food and drug administration approvals. JAMA Intern Med 175(12):1992–1994CrossRefGoogle Scholar
  20. Long GV, Atkinson V, Ascierto PA, Robert C, Hassel JC, Rutkowski P, Savage KJ, Taylor F, Coon C, Gilloteau I, Dastani HB, Waxman IM, Abernethy AP (2016) Effect of nivolumab on health-related quality of life in patients with treatment-naive advanced melanoma: results from the phase III CheckMate 066 study. Ann Oncol 27(10):1940–1946.  https://doi.org/10.1093/annonc/mdw265CrossRefPubMedPubMedCentralGoogle Scholar
  21. Maione P, Perrone F, Gallo C, Manzione L, Piantedosi F, Barbera S, Cigolari S, Rosetti F, Piazza E, Robbiati SF, Bertetto O, Novello S, Migliorino MR, Favaretto A, Spatafora M, Ferrau F, Frontini L, Bearz A, Repetto L, Gridelli C, Barletta E, Barzelloni ML, Iaffaioli RV, De Maio E, Di Maio M, De Feo G, Sigoriello G, Chiodini P, Cioffi A, Guardasole V, Angelini V, Rossi A, Bilancia D, Germano D, Lamberti A, Pontillo V, Brancaccio L, Renda F, Romano F, Esani G, Gambaro A, Vinante O, Azzarello G, Clerici M, Bollina R, Belloni P, Sannicolo M, Ciuffreda L, Parello G, Cabiddu M, Sacco C, Sibau A, Porcile G, Castiglione F, Ostellino O, Monfardini S, Stefani M, Scagliotti G, Selvaggi G, De Marinis F, Martelli O, Gasparini G, Morabito A, Gattuso D, Colucci G, Galetta D, Giotta F, Gebbia V, Borsellino N, Testa A, Malaponte E, Capuano MA, Angiolillo M, Sollitto F, Tirelli U, Spazzapan S, Adamo V, Altavilla G, Scimone A, Hopps MR, Tartamella F, Ianniello GP, Tinessa V, Failla G, Bordonaro R, Gebbia N, Valerio MR, D’Aprile M, Veltri E, Tonato M, Darwish S, Romito S, Carrozza F, Barni S, Ardizzoia A, Corradini GM, Pavia G, Belli M, Colantuoni G, Galligioni E, Caffo O, Labianca R, Quadri A, Cortesi E, D’Auria G, Fava S, Calcagno A, Luporini G, Locatelli MC, Di Costanzo F, Gasperoni S, Isa L, Candido P, Gaion F, Palazzolo G, Nettis G, Annamaria A, Rinaldi M, Lopez M, Felletti R, Di Negro GB, Rossi N, Calandriello A, Maiorino L, Mattioli R, Celano A, Schiavon S, Illiano A, Raucci CA, Caruso M, Foa P, Tonini G, Curcio C, Cazzaniga M (2005) Pretreatment quality of life and functional status assessment significantly predict survival of elderly patients with advanced non-small-cell lung cancer receiving chemotherapy: a prognostic analysis of the multicenter Italian lung cancer in the elderly study. J Clin Oncol 23(28):6865–6872.  https://doi.org/10.1200/JCO.2005.02.527CrossRefPubMedGoogle Scholar
  22. McPherson CJ, Addington-Hall JM (2003) Judging the quality of care at the end of life: can proxies provide reliable information? Soc Sci Med 1(56):95–109CrossRefGoogle Scholar
  23. Patrick DL, Burke LB, Gwaltney CJ, Leidy NK, Martin ML, Molsen E, Ring L (2011) Content validity–establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO good research practices task force report: part 1–eliciting concepts for a new PRO instrument. Value Health 14(8):967–977.  https://doi.org/10.1016/j.jval.2011.06.014CrossRefPubMedGoogle Scholar
  24. Pompili C, Salati M, Refai M, Berardi R, Onofri A, Mazzanti P, Brunelli A (2013) Preoperative quality of life predicts survival following pulmonary resection in stage I non-small-cell lung cancer. Eur J Cardiothorac Surg 43(5):905–910.  https://doi.org/10.1093/ejcts/ezs532CrossRefPubMedGoogle Scholar
  25. Quinten C, Maringwa J, Gotay CC, Martinelli F, Coens C, Reeve BB, Flechtner H, Greimel E, King M, Osoba D, Cleeland C, Ringash J, Schmucker-Von Koch J, Taphoorn MJ, Weis J, Bottomley A (2011) Patient self-reports of symptoms and clinician ratings as predictors of overall cancer survival. J Natl Cancer Inst 103(24):1851–1858.  https://doi.org/10.1093/jnci/djr485CrossRefPubMedPubMedCentralGoogle Scholar
  26. Ryan M, Farrar S (2000) Using conjoint analysis to elicit preferences for health care. BMJ 320(7248):1530–1533CrossRefGoogle Scholar
  27. Sloan JA, Zhao X, Novotny PJ, Wampfler J, Garces Y, Clark MM, Yang P (2012) Relationship between deficits in overall quality of life and non-small-cell lung cancer survival. J Clin Oncol 30(13):1498–1504.  https://doi.org/10.1200/JCO.2010.33.4631CrossRefPubMedPubMedCentralGoogle Scholar
  28. Svensson S, Menkes DB, Lexchin J (2013) Surrogate outcomes in clinical trials: a cautionary tale. JAMA Intern Med 173(8):611–612CrossRefGoogle Scholar
  29. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92(3):205–216 (European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada)CrossRefGoogle Scholar
  30. Toumi M (2016) Patient reported outcomes module. European Market Access University Diploma, ParisGoogle Scholar
  31. US Food and Drug Administration Guidance for Industry: Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labelling Claims. (2009). Rockville, MD: Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and ResearchGoogle Scholar
  32. WHO (1946) Preamble to the Constitution of the World Health Organization as adopted by the International Health Conference, signed on 22 July 1946 by the representatives of 61 States and entered into force on 7 April 1948. Official Records of the World Health Organization, no. 2, p. 100. World Health Organization, New YorkGoogle Scholar
  33. Willke RJ, Burke LB, Erickson P (2004) Measuring treatment impact: a review of patient-reported outcomes and other efficacy endpoints in approved product labels. Control Clin Trials 25(6):535–552.  https://doi.org/10.1016/j.cct.2004.09.003CrossRefGoogle Scholar
  34. Xiao C, Polomano R, Bruner DW (2013) Comparison between patient-reported and clinician-observed symptoms in oncology. Cancer Nurs 36(6):E1–E16.  https://doi.org/10.1097/NCC.0b013e318269040fCrossRefGoogle Scholar
  35. Zagadailov E, Fine M, Shields A (2013) Patient-reported outcomes are changing the landscape in oncology care: challenges and opportunities for payers. Am Health Drug Benefits 6(5):264–274PubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Mondher Toumi
    • 1
  • Szymon Jarosławski
    • 1
  • Christos Chouhaid
    • 2
  • Bruno Fallissard
    • 3
  • P. Auquier
    • 1
  1. 1.Public Health Department, Research Unit EA 3279Aix-Marseille UniversityMarseilleFrance
  2. 2.Centre Hospitalier Intercommunal, DHU-ATVBCréteilFrance
  3. 3.INSERM Unit U669 (Public Health and Mental Health)University Paris-SudOrsayFrance

Personalised recommendations